Unknown PHASE2 INTERVENTIONAL 2-arm NCT06284746

Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer

Clinical Efficacy and Safety of Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Resectable Gastric Cancer

Sponsor: Lin Chen

Conditions Efficacy HER2 Negative Locally Advanced Gastric Carcinoma Safety

Interventions SOX/XELOX Tirolizumab+SOX/XELOX

Updated 4 times since 2024 Last updated: Feb 28, 2024 Started: Oct 1, 2023 Primary completion: Apr 30, 2025 Completion: Jul 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Efficacy and HER2 Negative, this trial is ongoing. The trial is conducted by Lin Chen and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Oct 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lin Chen

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China